Loss of alveolar type 2 cells (AEC2s) and the ectopic appearance of basal cells in the alveoli
characterize severe lung injuries such as idiopathic pulmonary fibrosis (IPF). Here we …

Idiopathic pulmonary fibrosis (IPF) is a fatal disease with limited treatment options. In this
study, we focus on the properties of airway basal cells (ABC) obtained from patients with IPF …

Repeated injury of the lung epithelium is proposed to be the main driver of idiopathic
pulmonary fibrosis (IPF). However, available therapies do not specifically target the …

Stem cells undergo dynamic changes in response to injury to regenerate lost cells.
However, the identity of transitional states and the mechanisms that drive their trajectories …

There are currently few treatment options for pulmonary fibrosis. Innovations may come from
a better understanding of the cellular origin of the characteristic fibrotic lesions. We have …

Aberrant epithelial reprogramming can induce metaplastic differentiation at sites of tissue
injury that culminates in transformed barriers composed of scar and metaplastic epithelium …

Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease arising from impaired
regeneration of the alveolar epithelium after injury. During regeneration, type 2 alveolar …

Rationale: Declining lung function in patients with interstitial lung disease is accompanied
by epithelial remodeling and progressive scarring of the gas-exchange region. There is a …

Idiopathic pulmonary fibrosis (IPF) is the prototypic progressive fibrotic interstitial lung
disease. Median survival is only 3 years, and treatment options are limited. IPF is thought to …

Mechanisms leading to fibroblast accumulation during pulmonary fibrogenesis remain
unclear. Although there is in vitro evidence of lung alveolar epithelial-to-mesenchymal …